Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL223631 | 1.00 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL3192032 | 1.00 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL6206953 | 1.00 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL98457 | 1.00 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL17816948 | 0.85 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL15143001 | 0.85 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL4124556 | 0.85 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL6479731 | 0.85 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL7158782 | 0.83 | POLB (0.58) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL6714428 | 0.83 | POLB (0.58) | POLBGAAALOX12KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CARDURION PHARMACEUTICALS, INC. (US) | 2024-06-04 | — | — | US | claimed |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | CELLTRION, INC. (KR) | 2023-04-20 | — | — | US | claimed |
| US-12533343-B2 | Method for preparing (−)-cibenzoline succinate | CELLTRION, INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-20250019381-A1 | PROCESS FOR THE SYNTHESIS OF 6-((3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL)-3-(TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-a]PYRAZIN-8-ONE | CARDURION PHARMACEUTICALS, INC. | 2025-01-16 | — | — | US | disclosed |
| US-20250002466-A1 | PROCESS FOR THE PREPARATION OF CENOBAMATE ANND INTERMEDIATES THEREOF | METROCHEM API PVT LTD | 2025-01-02 | — | — | US | disclosed |
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CARDURION PHARMACEUTICALS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-11860084-B2 | Quantitative auxiliary-free chirality sensing with a metal probe | GEORGETOWN UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11860084-B2 | Quantitative auxiliary-free chirality sensing with a metal probe | GEORGETOWN UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2023170164-A1 | METHOD FOR PROVIDING A LABELED SINGLE ISOMERIC CHEMICAL ENTITY TARGETING VECTOR BASED ON THE USE OF A SYMMETRICAL DIENE | UNIVERSITY OF COPENHAGEN (DK) | 2023-09-14 | — | — | WO | disclosed |
| US-20230183244-A1 | METHODS OF MAKING AND USING PDE9 INHIBITORS | CARDURION PHARMACEUTICALS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | CELLTRION, INC. (KR) | 2023-04-20 | — | — | US | disclosed |
| US-11542492-B2 | Ligand-directed covalent modification of protein | CELGENE CAR LLC (BM) | 2023-01-03 | — | — | US | disclosed |
| US-11370795-B2 | Process for the synthesis of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | Imara Inc. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220113247-A1 | QUANTITATIVE AUXILIARY-FREE CHIRALITY SENSING WITH A METAL PROBE | GEORGETOWN UNIVERSITY | 2022-04-14 | — | — | US | disclosed |
| US-7157116-B2 | Method for the production of plane-parallel platelets by using organic separating agents | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CDK8, PRMT8, RPS8 | POLB 704/4885GAA 1985/4885ALOX12 3987/4885 |
| US-11542492-B2 | Ligand-directed covalent modification of protein | PTMS, SPR, DNPEP | POLB 4071/4885GAA 354/4885ALOX12 3300/4885 |
| US-20230183244-A1 | METHODS OF MAKING AND USING PDE9 INHIBITORS | PDE9A, PDE4B, PDE12 | POLB 486/4885GAA 129/4885ALOX12 2575/4885 |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | SDHA, SDHB, ALDH5A1 | POLB 2046/4885GAA 1066/4885ALOX12 3784/4885 |
| US-20250002466-A1 | PROCESS FOR THE PREPARATION OF CENOBAMATE ANND INTERMEDIATES THEREOF | TALDO1, AURKB, PGD | POLB 493/4885GAA 1224/4885ALOX12 1230/4885 |
| US-20250019381-A1 | PROCESS FOR THE SYNTHESIS OF 6-((3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL)-3-(TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-a]PYRAZIN-8-ONE | CDK8, PRMT8, DHPS | POLB 896/4885GAA 2037/4885ALOX12 3935/4885 |
| US-11370795-B2 | Process for the synthesis of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | TYMS, TKT, TPMT | POLB 595/4885GAA 840/4885ALOX12 3914/4885 |
| US-12533343-B2 | Method for preparing (−)-cibenzoline succinate | CIP2A, CACNA1A, SDHA | POLB 1578/4885GAA 1808/4885ALOX12 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.